Participant distribution through Week 96. Disposition is shown through the Week 96 data cutoff (August 14, 2018).

ARV, antiretroviral; CMV, cytomegalovirus. aThe 2 most common reasons for not meeting study criteria were >2 ARV classes remaining at screening and/or not failing current ARV regimen with a confirmed plasma HIV-1 RNA ≥400 copies/mL. b4 participants in the Randomized Cohort withdrew before starting open-label fostemsavir treatment (1 in the placebo group who died of community-acquired pneumonia on Day 11 and 3 in the fostemsavir group: 1 lost to follow-up, 1 protocol deviation, 1 for non-serious adverse events). c5 participants died after discontinuing the study: 3 in the Randomized Cohort (2 withdrew for hospice and died from squamous cell carcinoma, 1 withdrew for non-compliance with study drug and died from pneumonia) and 2 in the Non-randomized Cohort (1 met QTc discontinuation criteria, 1 withdrew because of CMV colitis). dUnable to comply with study visits (n=1), undetectable HIV-1 RNA before randomization (n=1), QTc discontinuation criteria (n=3). eQTc discontinuation criteria (n=4).